PRESS RELEASE

Tuesday February 15

Company Press Release

SOURCE: BioMedicines, Inc.

BioMedicines, Inc. Initiates Phase 1b Study with Biomed 101 in Patients with Kidney Cancer

ALAMEDA, Calif., Feb15 -- BioMedicines, Inc. today announced that it has initiated enrollment of patients in a Phase 1b clinical trial in kidney cancer patients with the company's investigational drug Biomed 101. The study will evaluate the safety, tolerability, and pharmacokinetics of multiple different doses of the investigational drug in conjunction with the approved cancer drug interleukin-2.

Clinical studies have shown that high doses of interleukin-2 can cause significant changes in blood pressure and dysfunction of the lungs, heart, and kidney.

"Cancer of the kidney and metastatic melanoma are life-threatening diseases. Although interleukin-2 can be effective in such patients, when high doses are required, toxicity is often severe," said Peter J. Langecker, M.D., Ph.D., Vice President of Clinical Affairs. "Biomed 101 is a novel drug intended to reduce these toxicities and to improve the tolerability and effectiveness of chemotherapy in these patients."

Biomed 101 binds to the leukotriene B4 receptor. Blocking this receptor in animal models prevents adverse effects from interleukin-2. Therefore, Biomed 101 may have the potential to improve the tolerability and response to treatment in patients who are treated with interleukin-2. This would include patients with kidney cancer, metastatic melanoma and possibly patients with AIDS. BioMedicines has exclusive worldwide commercial rights to Biomed 101.

BioMedicines, Inc., a privately held pharmaceutical company, is developing first line therapies for the treatment of cancer and infectious diseases. The company specializes in redirecting the development of drugs to new and more valuable indications. The company has current development and/or commercialization agreements with Boehringer Ingelheim, Schering AG, and G.D. Searle & Co. BioMedicines is headquartered in Alameda, California. More information about the company is available at www.biomedicinesinc.com.

| Back |